Solta Medical — Thermage — Merger or Acquisition (August 2008)
21 slides from Solta Medical's merger presentation, Aug 13, 2008
Slide 1: Slide 1
Slide 2: Thermage, Inc.
Thermage, Inc. (Nasdaq: THRM) Stephen Fanning Chairman and CEO August 12, 2008
Slide 3: Additional Information and Where You Can Find It
Additional Information and Where You Can Find It This communication may be deemed to be solicitation material in respect of the proposed transaction between Thermage and Reliant. In connection with the transaction, Thermage filed a registration statement on Form S-4 with the SEC containing a proxy s
Slide 4: Forward Looking Statements
Forward Looking Statements Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding potential transaction timing, projected financial results, and anticipated cost
Slide 5: Pioneer of fractional technology
• Pioneer of fractional technology • One of the most recognized and fastest growing brands in aesthetics • Large installed base of over 1,700 • Growing consumable revenue stream from tip sales leading to increased margins • A track record of innovation and a strong product pipeline • Broad patent pr
Slide 6: Creating a Global Leader: Strategic and Financial Rationale
Financial Rationale Strategic Rationale Creating a Global Leader • Creates industry leading recurring revenue model • Significant cost synergy opportunities benefiting from proximity of headquarters • Anticipated cash flow generation of over $15 million in 2009 • Expected to be accretive to GAAP EPS
Slide 7: Reliant Product Overview
Fraxel re:pair Fraxel re:fine Fraxel re:store Reliant Product Overview $79,000 $119,000 $129,000 System – List Price $400 $400 $400 Treatment Tip – List Price 5-6 full face treatments 3-5 full face treatments 1 full face treatment Approximate tip life Yes 1-2 Ablative January 2008 Yes Yes Consumable
Slide 8: Superior Fractional Technology
Superior Fractional Technology • Continuous motion scanning technology • Faster treatments • More uniform treatments • More effective results • Simpler, safer treatments • Greater reliability at total lower cost of ownership • Wide range in depth of treatment
Slide 9: Thermage
a ey) Thermage
Slide 10: Slide 10
Slide 11: Slide 11
Slide 12: Creating One of the Largest Sales Forces in Aesthetic Devices
Largest Bifurcated U.S. Sales Force Focus on Disposables Focus on Generators Enhances Market Penetration Creating One of the Largest Sales Forces in Aesthetic Devices
Slide 13: Enhanced Opportunity to Grow Consumable Revenue Stream
Thermage $24.6mm Thermage >2,500 Enhanced Opportunity to Grow Consumable Revenue Stream Treatment Tips and Consumables Revenue Months Ending June 30, • Dedicated consumables sales force markets to Reliant’s installed base • Proven cooperative marketing campaigns with physicians • Enhanced resources
Slide 14: Combining Two Highly Complementary Business Models
Combining Two Highly Complementary Business Models Revenue Streams for the 6 Months Ending June 30, 2008 72% 26% 2% 23% 72% 5% 45% 51% 4% 0% 20% 40% 60% 80% 100% Thermage Reliant NewCo Tips Systems Other
Slide 15: Key Financial Considerations
Key Financial Considerations
Slide 16: Reliant Income Statement: Systems and Consumables Driving Revenue Growth
Income Statement Year Ending 3 Months Ending ($ in millions) 12/31/2007 3/31/2008 6/30/2008 Systems and Consumables Driving Revenue Growth at Reliant Fraxel’s Continued Strong Growth Prospects • Continued momentum for re:pair • Pending foreign registration clearances for re:pair • Expanded applicati
Slide 17: Reliant Has Been One of the Highest Growth Aesthetics Companies
Reliant Has Been One of the Highest Growth Aesthetics Companies An Industry Leader in Revenue Growth Note: Growth shown as compared to the quarter of the previous year Index consists of CLZR, CUTR, CYNO, PMTI, and ELOS CLZR and ELOS Q2 ’08 revenue from consensus estimates 23% 12% 19% 11% 1% 1% 19% 1
Slide 18: Reliant Achieves Break-Even Non-GAAP Operating Income
Income Statement Year Ending 3 Months Ending 3 Months Ending ($ in millions) 12/31/07 % of Rev 3/31/08 % of Rev 6/30/08 % of Rev Comments Reliant Achieves Break-Even Non- GAAP Operating Income* *Non-GAAP Operating Income excludes SBC and extraordinary charges Net Revenues $70.5 100% $18.4 100% $22.6
Slide 19: Substantial Synergies Identified
Substantial Synergies Identified Headcount Related – 66 positions • Sales $2.2mm • Marketing $2.3mm • Operations $1.4mm • G&A $3.4mm TOTAL HEADCOUNT $9.3mm Other Costs • Marketing $2.0mm • Facilities $0.5mm • R&D $1.0mm • Consulting, Legal, Insurance, Audit $1.2mm TOTAL OTHER $4.7mm TOTAL SYNERGIES
Slide 20: Benefit From Economies of Scale
Benefit From Economies of Scale Q2 ’08 Operating Expenses as a % of Revenue Avg. of 54% Avg. of 67% $39 Q2 ’08 Revenue ($ in millions) $40 $38 $40 $25 $23 $18 $23 CLZR and ELOS from analyst estimates *Includes 25% of $14mm in synergies, or $3.5mm in synergies 61% Including Synergies* 69% Excluding S
Slide 21: Projected Liquidity of Combined Company
Projected Liquidity of Combined Company Cash $52.2mm $25mm Cash Paid to Reliant at Close $0 $5mm Cash Lent to Reliant $8mm Transaction /One-Time Expenses Cash ~$16mm $1mm Repayment of Assumed Debt and Interest 6/30/08 12/31/08 $2.5mm Reliant Cash Assumed 12/31/09 Estimated Cash Flow from Operations